November 29, 2022
Loading...
You are here:  Home  >  'Amgen'  -  Page 67
Latest

Patent ruling a lucrative gift for Amgen

By   /  Friday, December 23rd, 2011  /  Top Stories  /  1 Comment

Thousand Oaks-based Amgen made national headlines on Dec. 15 when it announced that Kevin Sharer, its longtime CEO who has drawn intense scrutiny for pay that ballooned while Amgen’s stock stagnated, will retire next year. But the more critical news to the future of Amgen, the biggest private-sector employer in Ventura County, was not that Read More →

Latest

Amgen CEO to step down

By   /  Thursday, December 15th, 2011  /  Latest news, Technology, Tri-County Public Companies  /  Comments Off on Amgen CEO to step down

Kevin Sharer, chairman and CEO of Amgen, is set to retire in May, the Thousand Oaks-based company said on Dec. 15. Current president and chief operating officer Robert Bradway will become the company’s new CEO. Sharer led Amgen, the largest private-sector employer in Ventura County, for 11 years. He oversaw the company’s transition from the Read More →

Latest

Amgen wraps up buyback auction

By   /  Thursday, December 8th, 2011  /  Latest news, Tri-County Public Companies  /  Comments Off on Amgen wraps up buyback auction

[wikichart align=”right” ticker=”NASDAQ:AMGN” showannotations=”true” livequote=”true” startdate=”08-06-2011″ enddate=”08-12-2011″ width=”300″ height=”245″] Amgen, based in Thousand Oaks, expects to repurchase 9.6 percent of its outstanding shares at a price of $60 per share after asking shareholders to name their price in a buyback auction. The biotech giant and major Ventura County employer said Dec. 8 it had completed Read More →

Latest

Amgen kicks off debt offering

By   /  Wednesday, November 30th, 2011  /  Banking & Finance, Latest news, Tri-County Public Companies  /  Comments Off on Amgen kicks off debt offering

[wikichart align=”right” ticker=”NASDAQ:AMGN” showannotations=”true” livequote=”true” startdate=”30-05-2011″ enddate=”30-11-2011″ width=”300″ height=”245″] Amgen has priced more than $1 billion in debt offerings as it loads up on cash for its massive stock buyback and dividend program. The company said it had priced $550 million of senior notes due 2018 and an additional $475 million in senior notes due Read More →

Latest

Amgen is Big Pharma’s newest player

By   /  Friday, November 11th, 2011  /  Columns, Opinion  /  Comments Off on Amgen is Big Pharma’s newest player

Nov. 7, 2011 should be remembered as the date when Amgen resigned its charter membership in the biotech growth club and joined Big Pharma.

Latest

Amgen launches $5B buyback

By   /  Monday, November 7th, 2011  /  Banking & Finance, Latest news, Tri-County Public Companies  /  Comments Off on Amgen launches $5B buyback

Amgen said Nov. 7 that it plans to buy back $5 billion of its shares as part of a push to return profit to stockholders. Shares of the Thousand Oaks-based drugmaker jumped 4.5 percent in morning trading. Moody’s Investors Service and Fitch Ratings lowered their ratings on Amgen debt after the announcement because the biotech Read More →

Latest

Editorial: Amgen’s corporate ethics need a checkup

By   /  Friday, October 28th, 2011  /  Editorials, Opinion  /  3 Comments

We call on Amgen’s executives to bring ethical sustainability to the company’s sales and marketing activities.